Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
Clinical trial NCT00369239 · COMPLETED
Trial details
- NCT number
- NCT00369239
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2006-03-01
- Enrollment
- 303
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.